About: Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses
Creator	Jones, Kevin Bleam, Maureen Deng, Yijun Laquerre, Sylvie Zhang, Yuanming Warren, Travis Guttieri, Mary Hruby, Dennis Bailey, Thomas Bolken, Tove Kickner, Shirley King, David Kirkwood-Watts, Dana Lund, S Pevear, Daniel Shurtleff, Amy Sperzel, Lindsey
Source	Elsevier; Medline; PMC
abstract	Abstract Category A arenaviruses as defined by the National Institute of Allergy and Infectious Diseases (NIAID) are human pathogens that could be weaponized by bioterrorists. Many of these deadly viruses require biosafety level-4 (BSL-4) containment for all laboratory work, which limits traditional laboratory high-throughput screening (HTS) for identification of small molecule inhibitors. For those reasons, a related BSL-2 New World arenavirus, Tacaribe virus, 67–78% identical to Junín virus at the amino acid level, was used in a HTS campaign where approximately 400,000 small molecule compounds were screened in a Tacaribe virus-induced cytopathic effect (CPE) assay. Compounds identified in this screen showed antiviral activity and specificity against not only Tacaribe virus, but also the Category A New World arenaviruses (Junín, Machupo, and Guanarito). Drug resistant variants were isolated, suggesting that these compounds act through inhibition of a viral protein, the viral glycoprotein (GP2), and not through cellular toxicity mechanisms. A lead compound, ST-294, has been chosen for drug development. This potent and selective compound, with good bioavailability, demonstrated protective anti-viral efficacy in a Tacaribe mouse challenge model. This series of compounds represent a new class of inhibitors that may warrant further development for potential inclusion in a strategic stockpile.
has issue date	2006-02-28(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2005.10.008
bibo:pmid	16343651
has license	els-covid
sha1sum (hex)	5bd9a33c12874606f5cd2cf9ad4ee1baf09cf8fc
schema:url	https://doi.org/10.1016/j.antiviral.2005.10.008
resource representing a document's title	Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses
has PubMed Central identifier	PMC7114356
has PubMed identifier	16343651
schema:publication	Antiviral Research
resource representing a document's body	covid:5bd9a33c12874606f5cd2cf9ad4ee1baf09cf8fc#body_text
is schema:about of	named entity 'identical' named entity 'acid' named entity 'lead compound' named entity 'chosen' named entity 'inclusion' named entity 'warrant' named entity 'CHARACTERIZATION' named entity 'IDENTIFICATION' named entity 'HEMORRHAGIC FEVER' named entity 'LEAD COMPOUND' named entity 'REPRESENT' named entity 'DRUG DEVELOPMENT' named entity 'BUT' named entity 'ANTIVIRAL ACTIVITY' named entity 'MOUSE' named entity 'CHOSEN' named entity 'INHIBITORS' named entity 'COMPOUND' named entity 'SERIES' named entity 'LABORATORY' named entity 'VIRUSES' named entity 'COULD BE' named entity 'RELATED' named entity 'HTS' named entity 'PATHOGENS' named entity 'CHALLENGE' named entity 'WORK' named entity 'IDENTIFIED' named entity 'INHIBITION' named entity 'BIOSAFETY LEVEL' named entity 'SMALL MOLECULE INHIBITOR' named entity 'TACARIBE VIRUS' named entity 'NEW WORLD ARENAVIRUSES' named entity 'CYTOPATHIC EFFECT' named entity 'NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES' named entity 'DEFINED' named entity 'POTENTIAL' named entity 'ARENAVIRUSES' named entity 'VIRAL GLYCOPROTEIN' named entity '400' named entity 'MODEL' named entity 'TOXICITY' named entity 'CATEGORY' named entity 'CELLULAR' named entity 'BIOAVAILABILITY' named entity 'IDENTICAL' named entity 'MECHANISMS' named entity 'AMINO ACID LEVEL' named entity 'SCREEN' named entity 'HUMAN' named entity 'CONTAINMENT' named entity 'IDENTIFICATION' named entity 'ASSAY' named entity 'THESE' named entity 'SELECTIVE' named entity 'APPROXIMATELY' named entity 'NEW' named entity 'DRUG RESISTANT' named entity 'ADN' named entity 'INDUCED' named entity 'REASONS' named entity 'STRATEGIC STOCKPILE' named entity 'DEVELOPMENT' named entity 'EFFICACY' named entity 'HIGH-THROUGHPUT SCREENING'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software